Palladium-Catalyzed C-S Coupling Breakthrough Enables Efficient Synthesis of JAK Inhibitor GDC-9918
A scientific research team has made a major breakthrough in the production process of the JAK1/2 inhibitor, GDC-9918. They have successfully resolved two key challenges in large-scale manufacturing, paving the way for the drug's industrialization.
A critical breakthrough has been made in the second-generation synthesis research of JAK1/2 inhibitor GDC-9918. The research team successfully addressed the inefficiency of palladium-catalyzed C-S coupling reactions, achieving efficient scaling from gram to kilogram levels through process optimization, thereby laying the foundation for the industrial production of inhaled formulation drug substances. Previously, the synthesis of GDC-9918 faced two major bottlenecks: poor selectivity in pyrazole methylation, with an N1/N2 isomer ratio of only 70:30 and a total yield of less than 50%; and the C-S coupling reaction required a high palladium catalyst loading of 12 mol%, resulting in residual palladium levels as high as 700 ppm. Additionally, 2-mercaptoethanol tended to form inert clusters with palladium, leading to rapid catalyst deactivation.
The research team achieved process upgrades through multiple innovations. In the pyrazole methylation step, methylhydrazine sulfate was used to replace traditional reagents, enabling a one-pot N1-selective condensation. The N1/N2 ratio improved to 89:11 and further reached 99.8:0.2 after crystallization purification, with the total yield increasing to 72%. For C-S coupling optimization, the substrate was switched from aryl chloride to aryl bromide, broadening the catalyst applicability and reducing the catalyst loading from over 10 mol% to 2 mol%. Through high-throughput screening, the weak base DIPEA combined with 1,4-dioxane was identified as optimal, and the (Xantphos)Pd G3 catalyst achieved a conversion rate of 92%. Innovatively, an in-situ OA complex was introduced as a "restart agent," increasing the conversion of stalled reactions from 29% to 96%. Coupled with slow feeding and inert atmosphere control, palladium deactivation was further suppressed. Subsequent purification steps also saw significant progress: potassium isopropyl xanthate (PIX) was employed to form soluble palladium complexes, reducing residual levels to <10 ppm. In the sulfide oxidation step, a Na₂WO₄/H₂O₂ catalytic system was adopted, paired with a mixed solvent to avoid product fouling, achieving a yield of over 96%.
This breakthrough not only resolves the synthesis quality and efficiency issues of GDC-9918 but also provides a low-loading, highly compatible solution for highly active palladium-catalyzed reactions, offering valuable insights for the development of similar drug substances.